Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis

  • Meta-Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Androgen deprivation therapy (ADT), which is used in the treatment of prostate cancer (PCa), is associated with increased morbidity. Severe bone loss is a major consequence of androgen ablation and with an increasing number of patients undergoing this treatment, the incidence of osteoporosis and fractures can be expected to increase with a significant impact on healthcare. To evaluate the prevalence of osteoporosis, we conducted a review of the literature on bone health in men with PCa undergoing ADT. A meta-analysis was conducted using the quality effects model, and sources of heterogeneity were further explored by consideration of discordant effect sizes of included studies in the meta-analysis and examining reasons thereof. Our analyses indicate that the prevalence of osteoporosis varies between 9 and 53 % with this variation partially explained by treatment duration, disease stage, ethnicity and site of osteoporosis measurement. While it is well known that a rapid decline in bone health amongst men with PCa on ADT occurs, this meta-analysis documents the high prevalence of osteoporosis in this population and reinforces the need of preventative approaches as part of usual care of PCa patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. W.P. Harris, E.A. Mostaghel, P.S. Nelson, B. Montgomery, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Oncol. 6(2), 76–85 (2009). doi:10.1038/ncpuro1296

    Article  CAS  Google Scholar 

  2. N. Sharifi, J.L. Gulley, W.L. Dahut, Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238–244 (2005). doi:10.1001/jama.294.2.238

    Article  CAS  PubMed  Google Scholar 

  3. M. Grossmann, E.J. Hamilton, C. Gilfillan, D. Bolton, D.L. Joon, J.D. Zajac, Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med. J. Aust. 194(6), 301–306 (2011)

    PubMed  Google Scholar 

  4. H.W. Herr, M. O’Sullivan, Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J. Urol. 163(6), 1743–1746 (2000). doi:10.1016/S0022-5347(05)67533-7

    Article  CAS  PubMed  Google Scholar 

  5. L.G. Taylor, S.E. Canfield, X.L. Du, Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11), 2388–2399 (2009). doi:10.1002/cncr.24283

    Article  PubMed  Google Scholar 

  6. C.S. Higano, Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat. Clin. Pract. Oncol. 5(1), 24–34 (2008)

    Article  Google Scholar 

  7. V. Seifert-Klauss, S. Fillenberg, H. Schneider, P. Luppa, D. Mueller, M. Kiechle, Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years. Climacteric 15(5), 433–440 (2012). doi:10.3109/13697137.2012.658110

    Article  CAS  PubMed  Google Scholar 

  8. L.J. Melton, E.A. Chrischilles, C. Cooper, A.W. Lane, B.L. Riggs, How many women have osteoporosis? J. Bone Miner. Res. 20(5), 886–892 (2005). doi:10.1359/jbmr.2005.20.5.886

    Article  PubMed  Google Scholar 

  9. A.S. Neto, M. Tobias-Machado, M.A. Esteves, M.D. Senra, M.L. Wroclawski, F.L. Fonseca, R.B. dos Reis, A.C. Pompeo, A. Del Giglio, A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol. 10(1), 9 (2010). doi:10.1186/1471-2490-10-9

    Article  Google Scholar 

  10. J.H. Littell, J. Corcoran, V.K. Pillai, Systematic reviews and meta-analysis. Pocket guides to social work research methods (Oxford University Press, Oxford, 2008)

    Book  Google Scholar 

  11. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006–1012 (2009). doi:10.1016/j.jclinepi.2009.06.005

    Article  PubMed  Google Scholar 

  12. D. Hoy, P. Brooks, A. Woolf, F. Blyth, L. March, C. Bain, P. Baker, E. Smith, R. Buchbinder, Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65(9), 934–939 (2012). doi:10.1016/j.jclinepi.2011.11.014

    Article  PubMed  Google Scholar 

  13. J.A.C. Sterne, D. Gavaghan, M. Egger, Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53(11), 1119–1129 (2000). doi:10.1016/s0895-4356(00)00242-0

    Article  CAS  PubMed  Google Scholar 

  14. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, L. Rushton, S.G. Moreno, Assessing publication bias in meta-analyses in the presence of between-study heterogeneity. J. R. Stat. Soc. 173(3), 575–591 (2010). doi:10.1111/j.1467-985X.2009.00629.x

    Article  Google Scholar 

  15. J.A. Kanis, L.J. Melton, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9(8), 1137–1141 (1994). doi:10.1002/jbmr.5650090802

    Article  CAS  PubMed  Google Scholar 

  16. B. Takkouche, C. Cadarso-Suárez, D. Spiegelman, Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am. J. Epidemiol. 150(2), 206–215 (1999)

    Article  CAS  PubMed  Google Scholar 

  17. R. Dersimonian, Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 15(12), 1237–1248 (1996). doi:10.1002/(sici)1097-0258(19960630)15:12<1237:aid-sim301>3.0.co;2-n

    Article  CAS  PubMed  Google Scholar 

  18. S.A. Doi, L. Thalib, A quality-effects model for meta-analysis. Epidemiology 19(1), 94–100 (2008). doi:10.1097/EDE.0b013e31815c24e7

    Article  PubMed  Google Scholar 

  19. S.A.R. Doi, J.J. Barendregt, E.L. Mozurkewich, Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp. Clin. Trials 32(2), 288–298 (2011). doi:10.1016/j.cct.2010.12.006

    Article  PubMed  Google Scholar 

  20. S. Senn, Trying to be precise about vagueness. Stat. Med. 26(7), 1417–1430 (2007). doi:10.1002/sim.2639

    Article  PubMed  Google Scholar 

  21. P.R. Sieber, F.M. Rommel, C.G. Theodoran, P.J. Russinko, C.A. Woodward, L. Schimke, The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer. J. Clin. Densitom. 15(3), 351–354 (2012). doi:10.1016/j.jocd.2012.01.010

    Article  PubMed  Google Scholar 

  22. E.Y. Yu, K.F. Kuo, R. Gulati, S. Chen, T.E. Gambol, S.P. Hall, P.Y. Jiang, P. Pitzel, C.S. Higano, Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30(15), 1864–1870 (2012). doi:10.1200/jco.2011.38.3745

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. W. Wang, T. Yuasa, N. Tsuchiya, S. Maita, T. Kumazawa, T. Inoue, M. Saito, Z. Ma, T. Obara, H. Tsuruta, S. Satoh, T. Habuchi, Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr. Relat Cancer 15(4), 943–952 (2008). doi:10.1677/erc-08-0116

    Article  CAS  PubMed  Google Scholar 

  24. T. Yuasa, S. Maita, N. Tsuchiya, S. Takahashi, K. Hatake, I. Fukui, T. Habuchi, Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. J. Urol. 183(4), e335 (2010). doi:10.1016/j.urology.2009.10.075

    Article  Google Scholar 

  25. J.H. Deng, L.P. Yang, L.S. Wang, D.F. Zhou, Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J. Androl. 6(1), 75–77 (2004)

    PubMed  Google Scholar 

  26. N.A. Spry, D.A. Galvao, R. Davies, S. La Bianca, D. Joseph, A. Davidson, R. Prince, Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 104(6), 806–812 (2009). doi:10.1111/j.1464-410X.2009.08458.x

    Article  CAS  PubMed  Google Scholar 

  27. J.M. Bruder, J.Z. Ma, J.W. Basler, M.D. Welch, Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67(1), 152–155 (2006). doi:10.1016/j.urology.2005.07.017

    Article  PubMed  Google Scholar 

  28. Z. Chen, M. Maricic, P. Nguyen, F.R. Ahmann, R. Bruhn, B.L. Dalkin, Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95(10), 2136–2144 (2002). doi:10.1002/cncr.10967

    Article  PubMed  Google Scholar 

  29. J.T. Wei, M. Gross, C.A. Jaffe, K. Gravlin, M. Lahaie, G.J. Faerber, K.A. Cooney, Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54(4), 607–611 (1999). doi:10.1016/S0090-4295(99)00301-5

    Article  CAS  PubMed  Google Scholar 

  30. M.M. Bernat, J. Pasini, Z. Marekovic, Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Coll. Antropol. 29(2), 589–591 (2005)

    PubMed  Google Scholar 

  31. J. Morote, J.P. Morin, A. Orsola, J.M. Abascal, C. Salvador, E. Trilla, C.X. Raventos, L. Cecchini, G. Encabo, J. Reventos, Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3), 500–504 (2007). doi:10.1016/j.urology.2006.11.002

    Article  PubMed  Google Scholar 

  32. J.L. Peters, A. Fairney, P. Kyd, A. Patel, S. Rogers, J.J. Webster, J.A. Vale, R.O.N. Witherow, Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis. 4(3), 161–166 (2001). doi:10.1038/sj.pcan.4500520

    Article  CAS  PubMed  Google Scholar 

  33. J. Planas, J. Morote, A. Orsola, C. Salvador, E. Trilla, L. Cecchini, C.X. Raventos, J.P. Morin, The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 99(4), 812–815 (2007). doi:10.1111/j.1464-410X.2006.06695.x

    Article  CAS  PubMed  Google Scholar 

  34. A.C. Looker, E.S. Orwoll, C.C. Johnston, R.L. Lindsay, H.W. Wahner, W.L. Dunn, M.S. Calvo, T.B. Harris, S.P. Heyse, Prevalence of low femoral bone density in older US adults from NHANES III. J. Bone Miner. Res. 12(11), 1761–1768 (1997). doi:10.1359/jbmr.1997.12.11.1761

    Article  CAS  PubMed  Google Scholar 

  35. J.E. Brown, R.J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, R.E. Coleman, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97(1), 59–69 (2005). doi:10.1093/jnci/dji002

    Article  CAS  PubMed  Google Scholar 

  36. R.S. Taichman, R.D. Loberg, R. Mehra, K.J. Pienta, The evolving biology and treatment of prostate cancer. J. Clin. Invest. 117(9), 2351–2361 (2007). doi:10.1172/JCI31791

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. C.J. Logothetis, S.H. Lin, Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 5(1), 21–28 (2005). doi:10.1038/nrc1528

    Article  CAS  PubMed  Google Scholar 

  38. E.T. Keller, J. Brown, Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem. 91(4), 718–729 (2004). doi:10.1002/jcb.10662

    Article  CAS  PubMed  Google Scholar 

  39. R.E. Coleman, P. Major, A. Lipton, J.E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y.J. Hei, J. Seaman, R. Cook, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925–4935 (2005). doi:10.1200/jco.2005.06.091

    Article  CAS  PubMed  Google Scholar 

  40. S. Rajpar, C. Massard, A. Laplanche, E. Tournay, M. Gross-Goupil, Y. Loriot, M. Di Palma, A. Bossi, B. Escudier, A. Chauchereau, K. Fizazi, Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann. Oncol. 21(9), 1864–1869 (2010). doi:10.1093/annonc/mdq037

    Article  CAS  PubMed  Google Scholar 

  41. S.A. Krum, Direct transcriptional targets of sex steroid hormones in bone. J. Cell. Biochem. 112(2), 401–408 (2011). doi:10.1002/jcb.22970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. S.L. Greenspan, P. Coates, S.M. Sereika, J.B. Nelson, D.L. Trump, N.M. Resnick, Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90(12), 6410–6417 (2005). doi:10.1210/jc.2005-0183

    Article  CAS  PubMed  Google Scholar 

  43. A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, W.M. O’Fallon, R. Eastell, S. Khosla, Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106(12), 1553 (2000). doi:10.1172/JCI10942

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. F. Haseen, L. Murray, C. Cardwell, J. O’Sullivan, M. Cantwell, The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J. Cancer Surviv. Res. Pract. 4(2), 128–139 (2010). doi:10.1007/s11764-009-0114-1

    Article  Google Scholar 

  45. S.M.H. Alibhai, S. Gogov, Z. Allibhai, Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit. Rev. Oncol. Hematol. 60(3), 201–215 (2006). doi:10.1016/j.critrevonc.2006.06.006

    Article  PubMed  Google Scholar 

  46. D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87(8), 3656–3661 (2002). doi:10.1210/jc.87.8.3656

    Article  CAS  PubMed  Google Scholar 

  47. E.J. Hamilton, A. Ghasem-Zadeh, E. Gianatti, D. Lim-Joon, D. Bolton, R. Zebaze, E. Seeman, J.D. Zajac, M. Grossmann, Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J. Clin. Endocrinol. Metab. 95(12), E456–E463 (2010). doi:10.1210/jc.2010-0902

    Article  CAS  PubMed  Google Scholar 

  48. L.J. Melton, M.M. Lieber, E.J. Atkinson, S.J. Achenbach, H. Zincke, T.M. Therneau, S. Khosla, Fracture risk in men with prostate cancer: a population-based study. J. Bone Miner. Res. 26(8), 1808–1815 (2011). doi:10.1002/jbmr.405

    Article  PubMed Central  PubMed  Google Scholar 

  49. M.R. Smith, W.C. Lee, J. Brandman, Q. Wang, M. Botteman, C.L. Pashos, Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol. 23(31), 7897–7903 (2005). doi:10.1200/jco.2004.00.6908

    Article  CAS  PubMed  Google Scholar 

  50. D. Gatti, M. Rossini, N. Zamberlan, V. Braga, E. Fracassi, S. Adami, Effect of aging on trabecular and compact bone components of proximal and ultradistal radius. Osteoporosis Int. 6(5), 355–360 (1996). doi:10.1007/BF01623008

    Article  CAS  Google Scholar 

  51. M.R. Smith, F.J. McGovern, A.L. Zietman, M.A. Fallon, D.L. Hayden, D.A. Schoenfeld, P.W. Kantoff, J.S. Finkelstein, Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345(13), 948–955 (2001). doi:10.1056/NEJMoa010845

    Article  CAS  PubMed  Google Scholar 

  52. A.B. Araujo, T.G. Travison, S.S. Harris, M.F. Holick, A.K. Turner, J.B. McKinlay, Race/ethnic differences in bone mineral density in men. Osteoporosis Int. 18(7), 943–953 (2007). doi:10.1007/s00198-006-0321-9

    Article  CAS  Google Scholar 

  53. E.M. Lewiecki, C.M. Gordon, S. Baim, M.B. Leonard, N.J. Bishop, M.-L. Bianchi, H.J. Kalkwarf, C.B. Langman, H. Plotkin, F. Rauch, B.S. Zemel, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, S. Silverman, International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6), 1115–1121 (2008). doi:10.1016/j.bone.2008.08.106

    Article  PubMed  Google Scholar 

  54. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L.J. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L.J. Denis, F. Recker, A. Berenguer, L. Määttänen, C.H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B.G. Blijenberg, S.M. Moss, H.J. de Koning, A. Auvinen, Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320–1328 (2009). doi:10.1056/NEJMoa0810084

    Article  PubMed  Google Scholar 

  55. M.R. Pradhan, A. Mandhani, S.S. Chipde, A. Srivastava, M. Singh, R. Kapoor, Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: does practice pattern match the guidelines? Indian J. Urol. 28(4), 399–404 (2012). doi:10.4103/0970-1591.105750

    Article  PubMed Central  PubMed  Google Scholar 

  56. T. Tanvetyanon, Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103(2), 237–241 (2005). doi:10.1002/cncr.20766

    Article  PubMed  Google Scholar 

  57. M. Nadler, S. Alibhai, P. Catton, C. Catton, M.J. To, J.M. Jones, Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 111(8), 1301–1309 (2013). doi:10.1111/j.1464-410X.2012.11777.x

    Article  CAS  PubMed  Google Scholar 

  58. S.M. Alibhai, L. Yun, A.M. Cheung, L. Paszat, Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307(3), 255–256 (2012)

    Article  CAS  PubMed  Google Scholar 

  59. National comprehensive cancer network: NCCN guidelines for prostate cancer (version 2.2013) (2013), http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 6 June 2013

  60. K. Sinningen, E. Tsourdi, M. Rauner, T. Rachner, C. Hamann, L. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42(1), 52–62 (2012). doi:10.1007/s12020-012-9696-x

    Article  CAS  PubMed  Google Scholar 

  61. R. Adler, Osteoporosis in men: recent progress. Endocrine 44(1), 40–46 (2013). doi:10.1007/s12020-013-9880-7

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Dietetics Research (C-DIET-R), School of Human Movement Studies, The University of Queensland, St Lucia, QLD, 4072, Australia

    Annie-Claude M. Lassemillante & Olivia R. L. Wright

  2. Mater Research, Raymond Terrace, South Brisbane, QLD, 4101, Australia

    Annie-Claude M. Lassemillante, John D. Hooper, John B. Prins & Olivia R. L. Wright

  3. Clinical Epidemiology Unit, School of Population Health, The University of Queensland, Herston, QLD, 4006, Australia

    Suhail A. R. Doi

  4. The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia

    John B. Prins

Authors
  1. Annie-Claude M. Lassemillante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suhail A. R. Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John D. Hooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John B. Prins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivia R. L. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annie-Claude M. Lassemillante.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 13 kb)

Supplementary material 2 (PDF 98 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lassemillante, AC.M., Doi, S.A.R., Hooper, J.D. et al. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45, 370–381 (2014). https://doi.org/10.1007/s12020-013-0083-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0083-z

Keywords

Search

Navigation